Sunpeaks Ventures Engages Former All-Star Player and Current Professional Basketball Head Coach as National Clotamin Spokesperson
SILVER SPRING, Md., March 17, 2012 /PRNewswire/ — Sunpeaks Ventures, Inc.’s (OTCBB: SNPK) (PINKSHEETS: SNPK) (the “Company” or “Sunpeaks Ventures”) wholly owned subsidiary Healthcare Distribution Specialist, LLC (“HDS”) is pleased to announce that they have entered into an agreement with former All-Star player and professional basketball coach, Paul Silas, as national spokesperson for Clotamin®. Clotamin is the world’s first specialized OTC multivitamin product designed exclusively for use by patients on Warfarin® and other anticoagulants (blood thinners).
Coach Silas is currently a professional basketball head coach and nominee for the Naismith Basketball Hall of Fame Class of 2012. During his 15+ year professional playing career, Silas collected more than 10,000 points and 10,000 rebounds, won three championship rings, and was twice named to the All-Star team. He ranks in the Top 20 for career games played, rebounding, and playoff rebounding. Since his retirement from active play, Paul has spent time as a popular professional basketball television commentator and as head coach with several professional basketball teams.
“We couldn’t be happier about having Paul as part of our team. We noticed his name when we were shipping his Clotamin and reached out to him about working with us and he couldn’t have been nicer,” stated Mackie A. Barch, CEO of Sunpeaks. “We plan to launch a ad campaign featuring Paul to help drive Clotamin into new markets and distribution channels.”
About Sunpeaks Ventures, Inc.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC (“HDS”), is a nationally focused, value-added distributor of specialty drugs and over-the-counter (“OTC”) branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed exclusively for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.
Contact: Financial Insights 888-248-8491 or firstname.lastname@example.org
Safe Harbor Statement
Information in this document constitute forward-looking statements or statements which may be deemed or construed to be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “forecast”, “anticipate”, “estimate”, “project”, “intend”, “expect”, “should”, “believe”, and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause Sunpeaks Ventures’ actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in Sunpeaks Ventures’ filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to Sunpeaks Ventures herein are expressly qualified in their entirety by the above-mentioned cautionary statement. Sunpeaks Ventures disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
SOURCE Sunpeaks Ventures, Inc.